Advertisement

Advertisement

2024 ASCO Annual Meeting

breast cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the...

prostate cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with l...

breast cancer

Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease

Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with h...

breast cancer

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understand...

breast cancer

Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who re...

leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with tre...

leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for p...

gynecologic cancers

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone ...

Lymphoma
Immunotherapy

CAR T-Cell Therapy in Patients With Central Nervous System Lymphoma

A chimeric antigen receptor (CAR) T-cell therapy approved for patients with large B-cell lymphoma has produced positive results in a pilot study involving patients with relapsed, treatment-resistant c...

Breast Cancer

Antibody-Drug Conjugate Plus Checkpoint Inhibitor for PD-L1–Positive, HR-Positive/HER2-Negative Breast Cancer

In patients with metastatic hormone receptor (HR)-positive/HER2-negative breast cancer unselected by PD-L1 status, adding the immune checkpoint inhibitor pembrolizumab to the antibody-drug conjugate s...

Leukemia

Shorter Durations of Venetoclax Yield Similar Response Rates Compared to Standard Course in AML

When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible pat...

Leukemia
Immunotherapy

Relapsed or Refractory B-Cell ALL: Novel CAR T-Cell Therapy Yields Strong Remission Rates

The novel anti-CD19 autologous chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblas...

American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration

The American Cancer Society (ACS) and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the ...

breast cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patien...

lung cancer

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of p...

multiple myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lena...

kidney cancer

Toni K. Choueiri, MD, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab...

leukemia
lymphoma

Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treate...

Lung Cancer

Lorlatinib vs Crizotinib for Advanced ALK-Positive NSCLC: Extended CROWN Follow-up

The CROWN study (ClinicalTrials.gov identifier NCT03052608) of lorlatinib, a brain-penetrant, third-generation ALK tyrosine kinase inhibitor, vs crizotinib, an inhibitor of receptor tyrosine kinases (...

Leukemia

Asciminib Shows Superior Efficacy vs Standard-of-Care Front-Line TKIs in CML

Over the past 2 decades, the development of tyrosine kinase inhibitors (TKIs) targeting the ATP-binding site of the constitutively activated tyrosine kinase in the fusion BCR::ABL1 protein has resulte...

Colorectal Cancer
Immunotherapy

Can a Novel Combination Therapy Improve Metastatic Colorectal Cancer Outcomes?

A novel combination comprising experimental immunotherapy drugs plus chemotherapy may improve survival outcomes in previously treated patients with metastatic colorectal cancer compared to the targete...

Prostate Cancer
Issues in Oncology
Genomics/Genetics

Differences in Prostate Cancer Genomics Among U.S. Veterans

Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by...

Hematologic Malignancies
Supportive Care
Issues in Oncology

Cyclophosphamide May Enable More Patients With High-Risk Hematologic Malignancies to Receive Stem Cell Transplants

A novel treatment strategy using cyclophosphamide-based graft-vs-host disease prophylaxis may enable more patients with high-risk hematologic malignancies to receive stem cell transplantation from mis...

Colorectal Cancer

AI-Based Virtual Patient Navigator Boosts Colonoscopy Adherence

A novel artificial intelligence (AI)-based virtual patient navigator, MyEleanor, improved colonoscopy uptake among U.S. patients who were previously nonadherent to prior colonoscopy appointments. Thes...

Gynecologic Cancers

Influence of Menopausal Hormone Therapy on Gynecologic Cancer Incidence and Mortality

In 2002, the federally funded Women’s Health Initiative—a randomized, placebo-controlled clinical trial investigating the effects of menopausal hormone therapy in healthy menopausal women—was abruptly...

Issues in Oncology

HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females

According to the Centers for Disease Control and Prevention, since the human papillomavirus (HPV) vaccine was introduced in the United States in 2006, HPV infections that cause most HPV-related cancer...

Breast Cancer
Survivorship

Most Breast Cancer Survivors Able to Achieve Pregnancy After Diagnosis, Study Finds

Research examining fertility preservation and pregnancy attempts among young women following a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of...

Advertisement

Advertisement




Advertisement